San Diego Life Sciences Roundup: Aragon, Illumina, CareFusion, & More

3/8/12Follow @bvbigelow

(Page 2 of 2)

San Diego innovation community, and bad for the personalized medicine movement.” About 90 percent of the world’s DNA sequencing output is now done on Illumina machines, according to a recent regulatory filing.

—San Diego-based CareFusion (NYSE: CFN) said it was acquiring Seattle’s Phacts, a consulting company that helps hospital pharmacies improve inventory management and reduce their costs. Terms of the deal were not disclosed. CareFusion said adding the Phacts group to its line of Pyxis inventory control equipment would help hospitals better manage their drug inventory controls and related business processes.

—San Diego’s Amylin Pharmaceuticals (NASDAQ: AMLN) said it plans to raise more than $200 million through a public offering of 13 million shares of its common stock. Amylin intends to use proceeds of the offering, which is expected to close by March 13, for expenses related to commericializing its extended-release exenatide (Bydureon) drug for diabetes, and for general corporate purposes.

—San Diego-based Lpath (OTCBB: LPTN), which specializes in lipidomics-based antibody therapeutics, said it has arranged to raise more than $9 million from various investors. Lpath sold more than 12 million shares, priced at 75 cents each; with each investor also receiving warrants to purchase additional shares at $1.10 over the next five years.

Histogen, the San Diego regenerative medicine startup, and Suneva Medical, a privately held aesthetics company based in San Diego, said they had signed a licensing agreement. Suneva acquired exclusive U.S. licensing rights to Histogen’s ReGenica branded line of physician-dispensed aesthetics and skin-care products. Suneva will make and market the products in the U.S. Financial terms were not disclosed.

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788 Follow @bvbigelow

Single Page Currently on Page: 1 2 previous page

By posting a comment, you agree to our terms and conditions.